Biodesix, Inc. BDSX recently announced a new post-market clinical validation study, published in CHEST Pulmonary Journal. The study reaffirms the previously established performance of the BDSX’s ...
BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...
LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation study ...
Deacetylase inhibitor (DACI) panobinostat in relapsed small cell lung cancer (SCLC) patients: Results of a multicenter phase II trial. Phase II trial of R-(-)-gossypol acetic acid (NSC 726190, AT-101) ...
Biodesix (BDSX) announced a new post-market clinical validation study was published in CHEST Pulmonary Journal that reaffirms the previously established performance of the Nodify CDT blood-based lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback